Cargando…

The Role of Glial Cells in Different Phases of Migraine: Lessons from Preclinical Studies

Migraine is a complex and debilitating neurological disease that affects 15% of the population worldwide. It is defined by the presence of recurrent severe attacks of disabling headache accompanied by other debilitating neurological symptoms. Important advancements have linked the trigeminovascular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vila-Pueyo, Marta, Gliga, Otilia, Gallardo, Víctor José, Pozo-Rosich, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454125/ https://www.ncbi.nlm.nih.gov/pubmed/37628733 http://dx.doi.org/10.3390/ijms241612553

Ejemplares similares

Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA
por: Torres-Ferrus, Marta, et al.
Publicado: (2020)

EHMTI-0361. Lack of differences in microrna expression profiles of blood cells in migraine
por: Vila-Pueyo, M, et al.
Publicado: (2014)

Impact of Puberty in Pediatric Migraine: A Pilot Prospective Study
por: Fonseca, Elena, et al.
Publicado: (2020)

EHMTI-0048. Epigenetic changes in a rat model of migraine with aura
por: Vila-Pueyo, M, et al.
Publicado: (2014)

OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse
por: Caronna, Edoardo, et al.
Publicado: (2018)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
por: Caronna, Edoardo, et al.
Publicado: (2021)

Cortical metabolic and structural differences in patients with chronic migraine. An exploratory (18)FDG-PET and MRI study
por: Torres-Ferrus, Marta, et al.
Publicado: (2021)

In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study
por: Alpuente, Alicia, et al.
Publicado: (2021)

Targeted 5-HT(1F) Therapies for Migraine
por: Vila-Pueyo, Marta
Publicado: (2018)

Editorial: Lifestyle modifications to manage migraine
por: Woldeamanuel, Yohannes W., et al.
Publicado: (2022)

Exploring sensory sensitivity, cortical excitability, and habituation in episodic migraine, as a function of age and disease severity, using the pattern-reversal task
por: Marti-Marca, Angela, et al.
Publicado: (2023)

Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials
por: Reuter, Uwe, et al.
Publicado: (2019)

Experiment in vivo: How COVID-19 Lifestyle Modifications Affect Migraine
por: Grozeva, Vesselina, et al.
Publicado: (2021)

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
por: Lipton, Richard B., et al.
Publicado: (2023)

Divergent influences of the locus coeruleus on migraine pathophysiology
por: Vila-Pueyo, Marta, et al.
Publicado: (2019)

A study of differential microRNA expression profile in migraine: the microMIG exploratory study
por: Gallardo, V. J., et al.
Publicado: (2023)

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
por: Pozo-Rosich, Patricia, et al.
Publicado: (2022)

Animal models of migraine and experimental techniques used to examine trigeminal sensory processing
por: Harriott, Andrea M., et al.
Publicado: (2019)

EHMTI-0270. Experience with onabotulinumtoxin type a in high-frequency episodic migraine
por: Pozo-Rosich, P, et al.
Publicado: (2014)

EHMTI-0283. Predictors of early response to onabotulinumtoxin type a in chronic migraine
por: Mas-Sala, N, et al.
Publicado: (2014)

Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
por: Pazdera, Ladislav, et al.
Publicado: (2021)

A systematic literature review on the role of glial cells in the pathomechanisms of migraine
por: Zhang, Shanshan, et al.
Publicado: (2023)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process
por: Steiner, Timothy J, et al.
Publicado: (2022)

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
por: Bendtsen, Lars, et al.
Publicado: (2018)

InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers
por: Gago-Veiga, AB, et al.
Publicado: (2021)

Exploring the neurobiology of the premonitory phase of migraine preclinically – a role for hypothalamic kappa opioid receptors?
por: Kopruszinski, Caroline M., et al.
Publicado: (2022)

Estimation of the density of veins from susceptibility-weighted imaging by using Mamdani fuzzy-type rule-based system. Investigating the neurovascular coupling in migraine
por: González, R., et al.
Publicado: (2023)

Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
por: Kudrow, David, et al.
Publicado: (2020)

EHMTI-0288. A clinical comparison demonstrates similarities between chronic and high frequency episodic migraine
por: Pozo-Rosich, P, et al.
Publicado: (2014)

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
por: Pozo-Rosich, Patricia, et al.
Publicado: (2021)

Cutaneous Allodynia in Migraine: A Narrative Review
por: Mínguez-Olaondo, Ane, et al.
Publicado: (2022)

Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings
por: Demartini, Chiara, et al.
Publicado: (2023)

Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study
por: Pozo-Rosich, Patricia, et al.
Publicado: (2021)

European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)
por: Sacco, Simona, et al.
Publicado: (2020)

Impaired K(+) binding to glial glutamate transporter EAAT1 in migraine
por: Kovermann, Peter, et al.
Publicado: (2017)

Spreading depression as a preclinical model of migraine
por: Harriott, Andrea M., et al.
Publicado: (2019)

Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas
por: Irimia, P., et al.
Publicado: (2021)

Headache as a Symptom of COVID-19: Narrative Review of 1-Year Research
por: Caronna, Edoardo, et al.
Publicado: (2021)

Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance
por: Sacco, Simona, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1mp16u4o39q63upcsat3ts055g